Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2240290/astrazeneca-azn-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2240290
Mar 13, 2024 - Astrazeneca (AZN) reachead $67.58 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.
0
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
https://www.zacks.com/stock/news/2243580/astrazeneca-azn-to-buy-fusion-pharmaceuticals-for-2-4b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243580
Mar 20, 2024 - AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
0
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2246316/astrazeneca-azn-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2246316
Mar 26, 2024 - In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
0
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
https://www.zacks.com/stock/news/2249013/astrazeneca-s-azn-rare-blood-disorder-drug-gets-fda-nod?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249013
Apr 02, 2024 - FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.
0
Top Research Reports for Berkshire Hathaway, Procter & Gamble & Adobe
https://www.zacks.com/commentary/2249662/top-research-reports-for-berkshire-hathaway-procter-gamble-adobe?cid=CS-ZC-FT-research_daily-2249662
Apr 03, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The Procter & Gamble Company (PG) and Adobe Inc. (ADBE).
0
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250526
Apr 04, 2024 - Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
0
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2251455/astrazeneca-azn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2251455
Apr 05, 2024 - Astrazeneca (AZN) closed the most recent trading day at $67.45, moving +0.16% from the previous trading session.
0
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
https://www.zacks.com/stock/news/2251823/astrazeneca-s-azn-enhertu-gets-fda-nod-for-solid-tumors?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251823
Apr 08, 2024 - FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.
0
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
https://www.zacks.com/stock/news/2252285/merck-mrk-begins-phase-ii-ii-ovarian-cancer-study-on-adc-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252285
Apr 08, 2024 - Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
0
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
0